The Use of U-500 in Patients With Extreme Insulin Resistance
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The Diabetes Control and Complication Trial (1) and the U.K. Prospective Diabetes Study (2,3), as well as other smaller trials (4), have established the benefit of treating type 1 and type 2 diabetes to levels of glycemia as close to normal as possible. These studies have formed the basis for the therapeutic targets set forth in the most recent American Diabetes Association (ADA) guidelines (5). There is a subset of patients classified by the ADA as having “other specific types of diabetes”; this group represents a major therapeutic challenge in terms of achieving glycemic goals (6). These patients have more extreme forms of insulin resistance than typical type 2 diabetic patients, and many manifest various syndromic classifications (Fig. 1). Furthermore, for the purpose of this discussion, we are including patients with extreme endogenous hyperinsulinemia or hyperglycemic patients who require doses of exogenous insulin of >200 units/day or in pediatric patients doses >3 units · kg−1 · day−1. This includes a subset of obese type 2 diabetic patients. Extreme forms of insulin resistance may also occur as a temporary state with pregnancy, with endocrinopathies and under various other stress conditions such as an infection, or with exogenous steroid use (Fig. 2). The practical issue of insulin management is essentially the same for all of these various patient categories. While we have defined the more extreme forms of insulin resistance whose requirements are >200 units insulin/day, this is clearly an arbitrary definition. Currently glycemic goals for both type 2 diabetes and “the other specific types of diabetes” are generally not being met. Part of the reason for this is that patients clearly are on insufficient doses of insulin. For instance, the median dose of insulin in a group of Pima Indians under treatment is 70 units/day …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508 · cited 1×
“It is clear that at least 40% of all diabetic patients will require insulin therapy to achieve therapeutic targets (7,8,26,27).”
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247 · cited 1×
“To achieve therapeutic goals for these patients, novel forms of therapy in addition to insulin are being introduced such as recombinant methionyl human leptin (19).”
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2005) · Diabetes Care · doi:10.2337/diacare.28.suppl_1.s37 · Cited by 830
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
The U.K. Prospective Diabetes Study. A review
Turner, R. C. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.c35 · Cited by 267 · cited 3×
“Therapy should also ameliorate the microvascular complications of hyperglycemia by 37% and result in a 21% decrease in the risk of any end point/ death related to diabetes with a decrease in HbA1c of 1% (2,3).”
Musso, C., Cochran, E., Moran, S. A., Skarulis, M. C., Oral, E. A., Taylor, S., & Gorden, P. (2004) · Medicine · doi:10.1097/01.md.0000133625.73570.54 · Cited by 264
Self-citationARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002) · Medicine · doi:10.1097/00005792-200203000-00001 · Cited by 223
Cited by
Insulin Receptor Signaling in Normal and Insulin-Resistant States
Boucher, J., Kleinridders, A., & Kahn, C. R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009191 · Cited by 1,473
Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery
Pridgen, E. M., Alexis, F., Kuo, T. T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R. S., Langer, R., & Farokhzad, O. C. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007049 · Cited by 405
Genetic Syndromes of Severe Insulin Resistance
Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P., & O'Rahilly, S. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0020 · Cited by 358
Self-citationPolymeric nanoparticle drug delivery technologies for oral delivery applications
Pridgen, E. M., Alexis, F., & Farokhzad, O. C. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1018175 · Cited by 269
Insulin autoimmune syndrome: from diagnosis to clinical management
Censi, S., Mian, C., & Betterle, C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.07.32 · Cited by 152
Metadata
- Authors
- Cochran, E., Musso, C., & Gorden, P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2005-05-01
- Volume
- 28
- Issue
- 5
- Pages
- 1240-1244
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2100462052
- Cited by
- 136
- References
- 13
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Use of U-500 in Patients With Extreme Insulin Resistance. https://app.cochat.ai/papers/10.2337/diacare.28.5.1240
- The paper
- Cochran, E., Musso, C., & Gorden, P. (2005). The Use of U-500 in Patients With Extreme Insulin Resistance. Diabetes Care. https://doi.org/10.2337/diacare.28.5.1240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.